With more than 30 years of experience, David Grimes focuses his practice on cross border and domestic M&A, securities, commercial and restructuring transactions. He represents companies and private equity funds in their acquisitions, dispositions and joint ventures. He also represents venture funds in their investments, and financial institutions in their financing transactions and restructurings. David counsels clients in various industries, including media, life sciences, financial institutions and industrials.
Prior to joining McDermott, David co-founded another AmLaw 100’s Paris office and was the former head of its cross-border transactions practice group.
Represented Anjac Health & Beauty, a French industrial group, in its acquisition of Cosmetix West, a California manufacturer of cosmetics, drugs, and food supplements
Represented HR Path, a global specialist in human resource solutions, in its first acquisition in the U.S., of Exaventures
Represented Radiall America, Inc., a U.S. subsidiary of the French group, Radiall SA, in its acquisition of Timbercon, Inc., a U.S. manufacturer of fiber optic and hybrid solutions for the military, aerospace, data communications, medical, and industrial markets
Represented Rhône Capital, a transatlantic private equity fund, in its acquisition of Rexair, the manufacturer and distributor of Rainbow® products for indoor environments from Newell Brands (NASDAQ: NWL).
Represented Petit Forestier Group, European leader in refrigeration rental, in its first US acquisition of Mendon Leasing*
Representing Dalian Wanda Group in its $1 billion purchase of Dick Clark productions*
Represented BBC Worldwide in its investment in BritBox, a British content-focused SVOD platform with its joint venture partners*
Represented Patheon Inc. (now part of Thermo Fisher Scientific), a publicly traded leading global provider of manufacturing and contract development services to the global pharmaceutical industry, in its $255 million acquisition of Banner Pharmacaps, a global specialty life sciences company *
Represented Talecris Biotherapeutics, a biologics company, in its purchase of numerous blood plasma centers, its $1 billion IPO and related 144A debt offering*
Represented ANV Holding B.V., a Dutch specialty insurer, in the US aspects of its purchase of Flagstone Holdings (UK) Limited*
Represented Bretèche Industrie (n/k/a LINXIS), then a portfolio company of Equistone Partners, in its first North American acquisition of Schick Solutions, an ingredient automation company*
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.